ResMed Shares Rise on RBC Capital Upgrade Amid Sleep Apnea Market Strength

NEW YORK — ResMed Inc. stock climbed 3% in trading Tuesday following an upgrade from RBC Capital Markets, which raised its price target for the medical device manufacturer to $262 per share. The rating change, moving from Sector Perform to Outperform, reflects renewed investor confidence in the company's market position within the obstructive sleep apnea sector.

Craig Wong-Pan, an analyst at RBC Capital Markets, cited several key factors driving the bullish outlook. Central to the upgrade is ResMed's continued dominance in the global market for devices treating obstructive sleep apnea. The firm highlighted robust revenue growth across major geographic regions, noting an 8% year-over-year increase in sleep device sales within the Americas. International expansion also showed significant momentum, with Rest of World sleep device sales surging 13% compared to the same period last year.

The analyst's report further pointed to competitive dynamics as a catalyst for ResMed's anticipated growth. A recent U.S. Food and Drug Administration recall involving a competitor's device has created market conditions favorable for ResMed to capture additional share. The regulatory action against the rival firm is expected to accelerate patient migration toward ResMed's established product lines, reinforcing its leadership status in the respiratory care industry.

ResMed, headquartered in San Diego, California, remains a primary supplier of continuous positive airway pressure machines and related monitoring software. The company has consistently focused on expanding its digital health ecosystem to complement its hardware sales, a strategy that appears to be yielding results as global demand for sleep therapy solutions rises. The 3% stock gain positions ResMed ahead of broader market movements, signaling that institutional investors are responding positively to the revised valuation.

The upgrade comes at a time when healthcare stocks are facing scrutiny over regulatory environments and supply chain logistics. While the recall of the competitor's device presents an immediate opportunity, long-term growth will depend on ResMed's ability to maintain its technological edge and navigate potential shifts in reimbursement policies across different markets.

Investors will be watching closely to see if the momentum from the upgrade translates into sustained trading volume over the coming weeks. The company has not yet issued a public statement regarding the specific details of the RBC analysis or the competitive landscape changes mentioned in the report. Market participants are also awaiting further data on whether the competitor's recall will result in prolonged disruptions that could alter the supply dynamics for sleep apnea devices globally.